Sep 15, 2021 / 03:44PM GMT
James Quigley - Morgan Stanley - Analyst
Great. So, good morning and good afternoon, everyone. I'm James Quigley, European pharma and biotech analyst at Morgan Stanley. It is my pleasure to welcome you all to this session with Hansa Biopharma. Today we're joined by Søren Tulstrup, the CEO. (Conference Instructions).
From a disclosure point of view, so for important disclosures, please see the Morgan Stanley research disclosure website, www.MorganStanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.
So, with all that explained, I think we can jump straight in. So, to start with the story, could you just give us a bit of an introduction to Hanson's platform and how your approach differs from other novel mechanisms to treat people with autoimmune diseases as well, so like antibodies, plasma exchange, FcRn to -- just to sort of set the scene about that platform?
Søren Tulstrup - Hansa Biopharma AB -
Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers